Cyplasin Biomedical Ltd. Announces Second U.S. Patent for Cyplasin

EDMONTON, Nov. 2 /CNW/ - Cyplasin Biomedical Ltd today announced that its U.S. Patent application Nr 10/501,098 entitled "Cytotoxic Cyplasin of the Sea Hare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive Recombinants" has been granted as US patent Number US 7,271,242 B2. The patent claims cover the production of a cytotoxic protein by mammalian cells and its use to treat cancer.

Back to news